Cardiovascular Effects of COVID-19
3. Discussion
The coronavirus disease (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has generated a pandemic that has heavily impacted the global population. However, the exact mechanisms underlying the disease progression of COVID-19 remain unknown.
Multiple evidence demonstrated that elevated blood troponin levels are strongly associated with poor prognosis in patients with COVID-19. In addition to the pneumonia-induced respiratory failure, thrombotic cardiovascular complications are increasingly gaining importance as a major COVID-19 presentation. This risk of thrombosis, if unaddressed, can cause severe damage even in patients with mild symptoms of pneumonia.
Professor Juan Carlos Kaski chairs the panel discussion on possible mechanisms of cardiovascular injuries in COVID-19 and how to manage them.
For the first two lectures in this webinar, please use the links below:
Chair
Juan Carlos Kaski, MD, DMsc, FESC, FACC, FAHA, FRCP
- Professor of Cardiovascular Science at St George’s, University of London
- Honorary Consultant Cardiologist at St George’s Hospital, NHS Trust, London
- Past President, International Society of Cardiovascular Pharmacotherapy
Panelists
Pablo Avanzas, MD, PhD, FESC
- Professor of Medicine, University of Oviedo, Oviedo, Spain
Koji Hasegawa, MD, PhD, FACC, FAHA, FAPSC
- Director, Division of Translational Research
- National Hospital Organization Kyoto Medical Center
- Clinical Professor, Faculty of Medicine, Kyoto University
Gheorghe-Andrei Dan, MD, PhD, FESC, FAHA, FACC, FEHRA
- Professor of Internal Medicine and Cardiology, Colentina University Hospital, Carol Davila
- Head, Internal Medicine Chair & Cardiology Department, Carol Davila University of Medicine and Pharmacy, Bucharest
Cardiovascular Effects of COVID-19
3. Discussion
Professor Juan Carlos Kaski